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We have upgraded a heavy-ion radiotherapy treatment-planning system to adapt for the 
layer-stacking irradiation method, which is to conform a variable SOBP to a target 
volume by means of dynamic control of the conventional beam-modifying devices. The 
biophysical model, the beam-setup logic, and the dose-calculation algorithm 
implemented for the layer-stacking method are described and the expected clinical 
usability is discussed.  
 
The layer-stacking method was integrated in perfect accordance with the ongoing 
conventional treatments so that the established protocols, which are the clinically 
optimized dose fractionation schemes, will still be valid. On the other hand, a 
simulation study indicated a substantial improvement of dose distribution with the 
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layer-stacking method though the significance may depend on the size, shape, and 
location of the tumor. The completed treatment system will provide an option for 
improved conformal radiotherapy without interfering with the conventional method and 
we expect a gradual expansion of the clinical cases applicable to the layer-stacking 
method. 
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INTRODUCTION 
  
The advantages of heavy-ion beams for radiotherapy are mainly owing to excellent 
physical properties and a concurrent radiobiological enhancement. A heavy-ion beam 
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can be precisely controlled to administrate the maximum dose at a tumor site, where the 
relative biological effectiveness (RBE) will be also at maximum, while a proton beam is 
usually modeled as a low-LET radiation with constant RBE between 1.0 and 1.1. Even 
though complexities and uncertainties in the fragmentation processes and in the 
biological responses for high LET have not been fully resolved yet, the large RBE at 
Bragg peak and the small lateral penumbra would be advantages of heavy-ion 
radiotherapy over proton or lighter particles.  
 
Clinical studies on carbon-ion radiotherapy have been carried out at National Institute of 
Radiological Sciences (NIRS) in Japan since 1994, using medical accelerator complex 
HIMAC.1 Over one thousand patients have been treated so far,2 where applied was the 
conventional irradiation method summarized as follows:3 A treatment beam is laterally 
broadened by a wobbler-scatterer system. A range-modulating device called a ridge 
filter produces a spread-out Bragg peak (SOBP), which is a depth span of a constant 
biologically effective dose, to cover the maximum width of the target. A range 
compensator adjusts the distal surface of the SOBP volume to match the distal surface 
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of the target volume together with a range shifter. Either a multileaf collimator (MLC) 
or a patient collimator defines the beam field covering the outer contour of the projected 
target. However, since the width of an actual target varies within the field, the fixed 
SOBP produced by a ridge filter results in undesirable dosage to the normal tissue in 
front of the target.  
 
The layer-stacking irradiation method was proposed to resolve this problem,4 and the 
HIMAC beam delivery system was upgraded to put this technique into practice.5 
Instead of conventional ridge filters, a single filter will be used to spread the Bragg peak 
to the size of several mm in water.6 The resultant small spread-out Bragg peak 
(minipeak) will be longitudinally scanned over the target volume in a stepwise manner. 
The target volume is longitudinally divided into slices, to each of which the minipeak is 
conformed using the MLC and the range shifter. A sequence of the irradiation steps 
with appropriate dose weights produces SOBP large enough to cover the target while 
trimming out the undesirable irradiations in front of the thin part of the target. 
Consequently, a variable SOBP coinciding to the target volume will be formed. The 
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data format for the interface between the treatment planning system and the beam 
delivery system has been upgraded to describe sequences of irradiation steps, which 
should be determined by the treatment planning system. 
 
The layer-stacking method may be positioned in between the conventional method and 
the spot-scanning method.7 In recent years, the spot-scanning method for particle 
radiotherapy has been practiced in Switzerland,8 and in Germany.9 The spot-scanning 
method has a potential to deliver truly optimum 3D dose distribution,10 but, at the same 
time, it requires a precise and complicated beam delivery system. The spot-scanning 
system for HIMAC should be practical only by an addition of a dedicated beam line, for 
which efforts are currently being made.11 On the other hand, this approach is to 
seamlessly improve the quality of treatment by means of an upgrade of the conventional 
treatment system without interfering with the ongoing clinical programs currently with 
over two hundred patients per year.  
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As a natural consequence of this approach, the layer-stacking method should be 
practiced in the scope of the current treatment protocols. Therefore, we decided not to 
refine the present theoretical framework, which the protocols are based on, at this point 
of time even though it may be too primitive and outdated compared to the recent studies 
on heavy-ion radiotherapy treatment planning.12 13 14 In this paper, we describe the 
modifications made to the existing treatment planning system for HIMAC,15 and we 
discuss the clinical usability of this irradiation method.  
 
 
MATERIALS AND METHODS 
  
Biophysical modeling 
  
For the conventional method, the biophysical modeling was not in the scope of 
treatment planning but was included in ridge-filter design and thus the treatment 
planning system only handles the resultant data tables of the depth-dose curves and the 
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biological effects of the range-modulated clinical beams. For the layer-stacking method, 
however, the range modulation is dynamically designed in treatment planning, for 
which we employed the same biophysical model based on the linear-quadratic (LQ) 
model as that for the conventional ridge filter design:16  
 
(1) The cell survival responses for carbon-ion radiation were extensively measured,17 
and the LQ model parameters α and β were obtained as a function of LET, where 
human salivary grand (HSG) tumor cell line was chosen to represent all the human cells 
because its response was found to be in the middle of a variety of biological species.18 
Figs. 1(a) and 1(b) show the adopted LQ parameters α and β as a function of LET.  
 
(2) The doses and dose-averaged LET's for the unmodulated beams were analytically 
calculated considering range straggling and projectile fragmentations based on the 
empirical model.19 Figs. 1(c) and 1(d) show the calculated dose and the dose-averaged 
LET for the unmodulated clinical beams of energies 290, 350, and 400 MeV per 
nucleon as a function of “beam depth” measured from the beam source. The LQ 
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parameters can then be related to the beam depth through the LET, ignoring ion species 
of the fragments and approximating the monochromatic LET by the dose-averaged 
LET. 
 
(3) The minipeak dose DG was obtained by the convoluting the effect of the minipeak 
filter to the unmodulated dose D1 and the effective LQ parameters αG and βG for the 
minipeak beam were calculated by dose averages;20 
 
€ 
DG (z) = D1(z + t)G(t)dt∫ , (1) 
 
€ 
αG (z) =
α(z + t)D1(z + t)G(t)dt∫
DG (z)
,  (2) 
 
€ 
βG (z) =
β(z + t)D1(z + t)G(t)dt∫
DG (z)
,  (3) 
 
where, G(t) is the pseudo-Gaussian probability function with mean 5.4 mm and standard 
deviation 2.5 mm for the distribution of the minipeak filter water-equivalent thickness  t. 
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Fig. 2(a) shows the calculated minipeak doses and the corresponding measured doses. 
The measured doses in the plateau region were higher than the calculated counterparts 
were, implying the incompleteness of the physical model in the calculation. We have 
therefore adopted the measured depth-dose curves in the subsequent calculations. In 
other words, the physical dose distributions are not part of the hypothetical biophysical 
model.  
 
(4) On the other hand, the calculation errors of the LET’s and the resultant RBE’s are 
ignored, since they are part of the adopted biophysical model. An RBE is in general a 
conversion factor from a physical dose to the 60Co dose for the same survival level, 
which was, however, too abstract for the conventional method, where the survival level 
had to be fixed for designing ridge filters. The clinical RBE was therefore defined as the 
RBE value at 10% survival level in the in vitro cell experiments,17 multiplied by the 
clinical factor to correct the effectiveness to that for in vivo. The clinical RBE of the 
minipeak as a function of depth is then formalized by; 
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€ 
RBEG (z) =
1.43 ⋅ 4.035 ⋅ 2βG (z)
αG (z)2 − 4βG (z)ln0.1 −αG (z)
,  (4) 
 
where 4.035 Gy is the experimentally obtained 10%-survival 60Co dose for the HSG 
cells and survival level 10%, corresponding to clinical dose of 5.77 GyE, was taken for 
the typical value for one fraction. Clinical factor 1.43 was originally to account for the 
difference between in vivo and in vitro but, in reality, it was introduced to preserve the 
GyE dose scale of the historical fast neutron radiotherapy at NIRS.18  
 
(5) The clinical dose in unit of GyE from the minipeak beam, CG, is defined simply by 
product; 
 
€ 
CG (z) = RBEG (z)DG (z).  (5) 
 
In this model, the RBE is dose-independent because it was defined at the fixed survival 
level irrelevantly to the actual cell survival to be caused by the irradiation. Figs. 2(b) 
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and 2(c) show the clinical RBE's and the clinical doses, respectively, for the minipeak 
beams.  
 
 
Range adjustment and field delineation 
 
The layer-stacking method and the conventional method share many features in the 
beam setup, such as the analysis of target depths using CT images, the choice of the 
optimum beam energy and wobbling condition, and the design of a range compensator. 
The essential difference lies in the stepwise control of the range shifter and MLC to 
conform SOBP to the target volume including the specified longitudinal and lateral 
margins.  
 
Fig. 3 shows an example of a spherical target, where the smooth line represents the 
cross section area of the target as a function of “compensated patient depth” measured 
from the entrance of the range compensator, with which the distal surface of the target is 
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fully equalized to the maximum depth. The partially numbered boxes represent the 
slices of the target. We chose the constant slice width of 2.5 mm in water to smoothly 
form a large SOBP.  
 
The beam range in a patient for each step is adjusted by the range shifter in such a way 
that the peak of the physical minipeak curve be located at the center of the 
corresponding target slice. Similarly, the field for each step is conformed by MLC to the 
corresponding target slice with a few constraints: (1) The opening between pairing left 
and right leaves below 10 mm is forced to 10 mm if not completely closed. (2) In a case 
where MLC field area would be smaller than 400 mm2, the MLC setup for the adjacent 
deeper slice is applied instead. (3) The MLC setup for the deepest slice, namely the 
largest field, is applied to the nearby slices within 30 mm in water. Constraints (1) and 
(2) are due to the limitation of the employed broad-beam dose calculation algorithm that 
is not capable to precisely handle a narrow beam while constraint (3) is to limit the 
variable SOBP to be at least 30 mm in water because it takes finite number of 
minipeaks to form a sufficient dose level.  
 14 
 
 
Step-weight optimization 
 
The objective for the step-dose weighting is to prescribe the specified nominal clinical 
dose to the given target volume as uniformly as possible. However, it is in principle 
impossible to achieve perfect uniformity over the variable-SOBP volume since the 
moving MLC partially blocks the fragmentation tail after the Bragg peak, which is the 
contribution of light ions originated in projectile fragmentations in flight. We therefore 
employed an iterative approach to determine the optimum dose weights for the steps.21  
 
The irradiation steps and the corresponding target slices are numbered with index i from 
the distal end (i = 1) to the proximal end (i = N). We take 2N−1 equally spaced samples 
of compensated patient depths with index j. As shown in Fig. 4, depth j = 1 is at the 
peak of the clinical dose from step i = 1 and depth j = 2N−1 is at the peak of the clinical 
dose from step i = N. The clinical dose at depth j from step i is given by; 
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€ 
CGij = CG zG + Ti −T1 + δ j −δ1( ) ,  (6) 
 
where constant zG is the beam depth where the clinical dose of minipeak beam is at 
maximum, variables Ti and δj are the range shifter thickness for step i and the 
compensated patient depth for depth j, respectively. The average clinical dose within the 
target at depth j, Cj, is calculated by formula;  
 
€ 
C j =
An − An+1( ) wiCGij
i=1
n
∑
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥ 
n= I j
N
∑
AI j
, (7) 
 
where Ai and wi are the field area and the dose weight, respectively, for step i. The 
minimum number of contributing steps, Ij, is identical to the number for the slice 
covering depth j, satisfying inequalities;  
 
€ 
TI j −T1 ≤ δ1 −δ j < TI j +1 −T1. (8) 
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All wi’s are initially set to 1 and are iteratively updated in order for Cj’s to approach the 
specified clinical dose C, by renormalizing wi’s by average of Cj/C over j with weights 
related to the dose contribution of step i to depth j;  
 
€ 
wi →
C AI jCGij
2
j=1
2N +1
∑
C jAI jCGij
2
j=1
2N +1
∑
wi , (9) 
 
where the empirically determined enhancement of the dose contribution, the square in 
CGij2, accelerates the convergence and the iteration will be repeated until no 
improvement has been observed.  
 
 
Dose calculation 
 
For the simplicity of the optimization process, the step-dose weights are determined 
under the implicit hypothesis such that the clinical dose is an additive parameter, which 
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is equivalent to the dose-averaged RBE model for mixed radiations.22 However, since 
the clinical dose distribution in a patient is the most important measure for a treatment 
plan, we strictly follow the biophysical model for the clinical dose calculation. Namely, 
the distributions of physical dose, dose-averaged α, and dose-averaged √β in the patient 
are calculated and then converted to the clinical dose distribution in analogy with Eqs. 
(4) and (5). The calculations showed a slight (max 2%) decrease of the RBE in the 
SOBP region while there were no differences in the plateau and tail regions, compared 
to the dose-averaged RBE model. This is because a large LET mixture occurs only in 
the SOBP region.  
 
The physical dose calculation is based on the same algorithm as that for the 
conventional method, the parallel broad-beam model, where the infinite focal distance is 
assumed and the transverse beam flow is totally ignored. The compensated patient 
depths are first calculated for all the calculation points with the ray-tracing technique. 
For each calculation point in each step, the compensated patient depth is converted to 
the beam depth by adding the range-shifter thickness and the offset for the materials in 
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the beam line, then converted to the broad-beam physical dose with the tabulated 
minipeak depth-dose function, and then multiplied by the penumbra factor given by the 
error function of the distance to the field boundary. The resultant physical doses from 
all the steps are accumulated to form the physical dose distribution. Since the amount of 
time-consuming ray-tracing calculation was minimized, the typical calculation time was 
only twice as much as that for the conventional method.  
 
In order to verify the dose consistency between the layer-stacking and conventional 
methods, we took an example of a cubic target to generate a fixed SOBP with both 
methods, for which we naively expected essentially the same range modulation. Fig. 5 
shows the resultant clinical dose, physical dose, and dose-averaged LET along the 
central-axis for both methods. The distributions of the layer-stacking irradiation actually 
agreed very well to the conventional counterparts except for the behaviors near the ends 
of the SOBP due to the artificial range straggling by the minipeak filter. Paganetti and 
Goitein reported equivalent phenomena for proton beams with various energy spreads.23 
The SOBP region for the layer-stacking irradiation made a perfect match to the target, 
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giving well symmetric 90% and 95% of the nominal clinical dose at the distal and 
proximal ends, respectively.  
 
 
Example calculations 
 
Variable SOBP formation 
 
We took an example of a T-shaped target in a water phantom prescribed 1 GyE with the 
layer-stacking beam. In Fig. 6(a), the grayscale represents the planned clinical dose 
distribution in the isocentric plane, showing the capability of the variable-SOBP 
formation conformal to the given target. Fig. 6(b) shows the planned and measured 
physical dose profiles at the thin and thick parts of the SOBP. The agreement between 
the measurement and the calculation indicates that the entire treatment system was fully 
functional for the layer-stacking irradiation.  
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Improvement of dose distribution 
 
We compared the layer-stacking irradiation and the conventional irradiation by applying 
them to the same clinical example on the treatment planning system. Figs. 7(a) and 7(b) 
show isodose plots for the layer-stacking beam and the conventional beam, respectively, 
applied to a large tumor in the bone and soft tissue region, where the superiority of the 
layer-stacking method is obvious by the improved matching between 90% isodose line 
and the target contour. Fig. 8 shows the dose histograms for the target and the patient 
skin that may be an organ at risk for this case, where the skin dose was significantly 
reduced with the layer-stacking method while the target was receiving almost the 
equivalent clinical dose. 
 
 
DISCUSSION 
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There certain are sources of inaccuracies and questionable hypotheses included in the 
present model: In the biophysical part, the overall fragmentation processes, the use of 
dose-averaged LET for LQ parameters when fragmentations and straggling are 
present,24 the dose-independent RBE that may be against the idea of the original LQ 
model, the use of the radiobiological responses of the single cell line, and the validity of 
the clinical factor are obviously the issues to be further investigated. In the physical 
beam part, the parallel broad-beam model should be improved to a better algorithm, as 
Petti reported,25 with a better CT-based patient model,26 and the position errors should 
be considered in the range compensator design.27 Even though efforts to resolve some 
of those problems were made,28 29 they have not yet been practiced at NIRS to avoid 
possible confusions in the middle of the clinical studies.  
 
The GyE dose scale should be an original dose scale rather than cobalt-Gy equivalent. 
However, it may be unreasonable to measure a high-LET radiation by the equivalent 
low-LET radiation, where expected are larger radiobiological complexities due to the 
indilect effects. Concequently, we needed clinical studies to optimize the treatment 
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protocols, namely, the prescription doses, fraction schedules, and the ways to add 
margins to the target, for individual tumors. In other words, the present treatments with 
HIMAC should not be too far from the ideal treatments regardless of the definition of 
the GyE.  
 
When we refine the biophysical model in the future, the use of the common set of the 
ridge filters for various tumor sites with various fraction doses, typically 3.6 GyE × 16 
fractions and 13.2 GyE × 4 fractions at present, will have to be reconsidered. It will be, 
however, difficult to fabricate many protocol-specific sets of ridge filters and to install 
them in the present HIMAC system. On the other hand, the layer-stacking method 
should be very adaptive to such a model change since the biological dose optimization 
is fully handled by the treatment planning system.  
 
As to the clinical usability of the layer-stacking method, we can generalize the result of 
the simulation study for the bone and soft tissue case: There will be substantial 
improvements over the conventional method for large targets when the incident beam 
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directions are limited. For a small target, the improvement will be naturally small and, 
in a multiport plan, the conventional method will be more conformal in analogy with the 
3D-conformal radiotherapy. Castro et al. also made similar studies and concluded that a 
reduction of the number of ports would be possible with the layer-stacking method for 
clinically equivalent conventional multiport treatments.30 However, there will be 
possible mismatches between the minipeak layers when large organ motions are present, 
which may deteriorate the target dose uniformity. Though Bortfeld et al. found that such 
side effects specific to dynamic delivery technques would be relatively small,31 we do 
not expect the layer-stacking method to completely replace the conventional method.  
 
The completed treatment system will provide an option for improved conformal 
radiotherapy without sacrificing the functionality of the conventional method and we 
expect a gradual expansion of the clinical cases applicable to the layer-stacking method. 
The layer-stacking method should not only be specific to heavy-ion radiotherapy but 
also be equivalently effective for proton radiotherapy, where, in addition, majority of 
the problems with he biophysical model will be much less significant.  
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CONCLUSIONS 
 
The treatment planning system for HIMAC has been upgraded to adapt for the 
layer-stacking irradiation method based on the identical biophysical model and the 
calculation algorithms as those for the conventional method. Therefore, the accumulated 
clinical experiences with HIMAC are still valid for the layer-stacking method and hence 
the clinical practice is straightforward.  
 
Improvement of dose distribution is expected with the layer-stacking method, though 
the significance may depend on size, shape, location of the tumor, and number of ports 
used to treat the patient. We expect that the conventional and layer-stacking methods 
will coexist in a complementary manner for a variety of clinical situations and, in 
general, addition of the layer-stacking method to the conventional particle treatment 
system should be a reasonable upgrade option for improved conformal radiotherapy. 
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FIG. 1. The adopted biophysical parameters for unmodulated clinical carbon 
beams; (a) LQ parameter α  and (b) LQ parameter β  as a function of carbon-ion 
LET, and (c) the physical dose and (d) the dose-averaged LET as a function of 
depth, where the solid, dashed, and dotted lines are for energies 290, 350, and 400 
MeV per nucleon, respectively. The doses are normalized to the depth-zero dose.  
 
FIG. 2. Physical and clinical doses and RBE as a function of depth for the 
minipeak beams; (a) the physical dose with the measured data shown as markers, 
(b) the clinical RBE, and (c) the clinical dose, where the solid, dashed, and dotted 
lines are for energies 290, 350, and 400 MeV per nucleon, respectively. The doses 
are normalized to the maximum physical dose. 
 
FIG. 3. The depth distribution for a range-compensated spherical target. The 
smooth line represents the cross section area of the target and the solid boxes 
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indicate the regions of target slices numbered from the distal side. The dashed 
boxes indicate the target slices corrected by the MLC constraints for the minimum 
field size and for the minimum SOBP width. 
 
FIG. 4. A schematic example for SOBP formation with depth-dose curves of the 
individual steps appropriately weighted for the prescribed dose of 1 GyE; (a) 
showing the extent of the SOBP with all the steps and (b) enlarged around the 
beam range only with the first four steps. The dashed lines indicate the extent of 
the SOBP. The dotted lines indicate sample depths numbered from the distal side.  
 
FIG. 5. A verification of equivalency between the layer-stacking and conventional 
irradiations; (a) clinical dose, (b) physical dose, and (c) dose-averaged LET where 
the solid and dashed lines show calculations for the layer-stacking and 
conventional irradiations, respectively, and the circles show measured data for the 
layer-stacking irradiation.  
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FIG. 6. An example of the dose calculation for the layer-stacking irradiation for a 
T-shaped (in z-x plane) target, where shown are (a) the clinical isodose plot in y=0 
plane with the overlaid target contours (solid: original, dashed: with margins) and 
(b) the physical dose profiles at the thick part (x = 30 mm) and at the thin part (x = 
−10 mm). The smooth lines and the circles show the calculation and the measured 
data, respectively. 
 
FIG. 7. Dose distribution plots for a tumor in the bone and soft tissue region; 
target contour and the isodose lines overlaid on the patient CT image for (a) the 
layer-stacking irradiation and (b) the conventional irradiation. The yellow line 
shows the target contour while the isodose lines are in colors of the corresponding 
dose-percentage numbers shown in the figure. 
 
FIG. 8. Dose distribution analysis for a tumor in the bone and soft tissue region; 
(a) differential dose-volume histogram for the clinical target volume and (b) 
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differential dose-surface histogram for the patient skin, where the solid and dashed 
lines indicate the layer-stacking and conventional irradiations, respectively.  
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